Table 2: Overall Survival, Grade (OS/gr) and values of Nivo in 1st and 2nd-line.
| Nivo in 1st- and 2nd-line | OS gains in days, grade (OS/gr) & HR | $4-week value (4-week cost × HR) | $C/LYG | Relative Value (RV) = ($100,000/LYG) |
| 1st-line: Nivo vs. dacarbazine, Melanoma | OS not reached HR 0.42 | 4,209 | - | - |
| 2nd-line: Nivo vs. everolimus, Renal cell | 162/A & 0.73 P = 0.002 | 7,315 | 289,496 | 0.35 |
| Nivo vs. docetaxel, squamous-NSCLC | 96/B & 0.59 P = 0.00025 | 5,912 | 488,524 | 0.20 |
| Nivo vs. docetaxel, non-squamous-NSCLC, CheckMate 057 | 84/C & 0.73 P = 0.0016 | 7,315 | 558,326 | 0.18 |
| Subset analysis in >10% PD-L1 | 264/A & 0.27 | 2,706 | 177,650 | 0.56 |
| Nivo vs. investigator's choice, SCCHN | 72/C & 0.70 P = 0.0101 | 7,015 | 651,430 | 0.15 |
| Subset analysis in >1.0 PD-L1, SCCHN | 123/B & 0.55 | 5,512 | 381,287 | 0.26 |